GlassScriptPhysician profile
Michael J Hickham
NPI 1518967793
$4,896.37
in general payments reported to CMS, 2019-2025
30 companies · $632 in 2025
The $632 reported for 2025 was more than what a typical Otolaryngology provider received nationally (typical 2025 total: $317).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $456 · 2020: $566 · 2021: $732 · 2022: $926 · 2023: $921 · 2024: $663 · 2025: $632.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,127 · Education: $88.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,127.18 |
| Education | $88.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $730.09 | 2019-2025 | |
| Glaxosmithkline, LLC. | $701.33 | 2021-2025 | Nucala, Trelegy Ellipta |
| Regeneron Healthcare Solutions, INC. | $523.44 | 2020-2025 | Dupixent |
| Optinose US, INC. | $422.84 | 2019-2024 | |
| Astrazeneca Pharmaceuticals LP | $414.66 | 2019-2024 | Airsupra |
| Abbvie INC. | $263.30 | 2022-2025 | |
| Stryker Corporation | $256.84 | 2021-2025 | Scopis Ent, Xpress Loprofile |
| Acclarent, INC | $240.81 | 2019-2021 | |
| Jazz Pharmaceuticals INC. | $190.79 | 2020-2022 | |
| Hill Dermaceuticals, INC. | $137.85 | 2020 | |
| Inspire Medical Systems, INC. | $129.40 | 2019 | |
| Hikma Pharmaceuticals USA | $124.09 | 2022-2024 | Ryaltris |
| Pfizer INC. | $99.07 | 2023-2024 | |
| Alk-Abello, INC | $98.78 | 2019-2022 | |
| Intersect Ent, INC. | $88.43 | 2021 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Acelrx Pharmaceuticals, INC. | $67.10 | 2022 | |
| Amgen INC. | $56.06 | 2025 | Tezspire |
| Sanofi-Aventis U.S. LLC | $54.95 | 2023 | |
| Biohaven Pharmaceutical Holding Company LTD. | $43.45 | 2022 | |
| Aerin Medical INC. | $40.43 | 2020-2021 | |
| Olympus America INC. | $30.92 | 2023 | |
| Merck Sharp & Dohme LLC | $29.77 | 2021-2023 | |
| Smith+Nephew, INC. | $28.78 | 2021 | |
| Medtronic USA, INC. | $25.67 | 2020 | |
| Kaleo, INC. | $19.22 | 2022 | |
| Novartis Pharmaceuticals Corporation | $18.31 | 2023 | |
| Lundbeck LLC | $17.68 | 2024 | Vyepti |
| Acell, INC. | $16.10 | 2020 | |
| Genentech USA, INC. | $13.16 | 2019 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $13.05 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Hickham listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.